JACKSON, Mich., Jan. 16, 2025 /PRNewswire/ -- CMS Energy announced today it will provide 2024 year-end results along with a business and financial outlook at 9:30 a.m. EST on Thursday, February 6, 2025.A webcast of the presentation will be available on CMS Energy's website, cmsenergy.com. An audio replay will be available approximately three hours after the webcast and will be archived for 30 days on CMS Energy's website in the "Investor Relations" section.CMS Energy (NYSE: CMS) is a Michigan-based energy c ...

CMS Energy Corporation (CMS) is making strategic investments to enhance its operations. CMS is also benefiting from delivering high-quality services to its consumers. The company is expanding its renewable power portfolio while eliminating coal-generating units.However, this Zacks Rank #3 (Hold) company is exposed to unfavorable costs associated with the shutdown of solid waste disposal facilities for coal ash.Factors Acting in Favor of CMS CMS Energy is investing heavily in infrastructure renovations and r ...

Medicare and Medicaid Coverage for Zepbound - Medicare Part D plans can now cover Eli Lilly's Zepbound for obstructive sleep apnea (OSA), expanding access to the drug which was previously not covered for weight loss [1][2] - Medicare Part D coverage for obesity drugs like Zepbound requires FDA approval for an additional medically accepted purpose, and prior authorization may be used to ensure proper usage [3] - State Medicaid programs must cover Zepbound if prescribed for OSA and Eli Lilly has signed the Medicaid drug rebate agreement, but coverage is not required if prescribed for weight loss [7][8] FDA Approval and Market Impact - Zepbound was approved by the FDA on Dec 20 for obesity and moderate-to-severe OSA, making it the first drug treatment for an estimated 20 million people with these conditions [4] - Demand for Zepbound has soared over the past year despite its $1,000 price tag before insurance [1] Comparative Coverage and Industry Trends - Medicare Part D plans also cover Novo Nordisk's Wegovy for its approved use of lowering cardiovascular risks, while diabetes counterparts Ozempic and Mounjaro are covered by Medicare and most insurance plans [5] - Both Eli Lilly and Novo Nordisk are studying their weight loss drugs for additional conditions like fatty liver disease, chronic kidney disease, and sleep apnea, which would require late-stage trial results and FDA approval for coverage [6] Policy and Cost Implications - The Biden administration proposed a rule in November to allow Medicare and Medicaid coverage for weight loss drugs, potentially giving millions access to weekly injectables but costing taxpayers up to $35 billion over the next decade [9]

CMS Energy Corporation (CMS) recently revealed that its primary subsidiary, Consumer Energy, has introduced a plan to upgrade its natural gas system, which provides gas to more than 1.8 million homes and businesses in Michigan.Details of CMS’ PlanPer the plan, the company will replace up to 10,000 old gas lines and add valves that can be operated remotely to handle emergencies faster. These improvements will make the system safer, more reliable and better for the environment while keeping it affordable for ...

At Energy Profits in Dividends, we seek to generate a 7%+ income yield by investing in a portfolio of energy stocks while minimizing our risk of principal loss. By subscribing, you will get access to our best ideas earlier than they are released to the general public (and many of them are not released at all) as well as far more in-depth research than we make available to everybody. In addition, all subscribers can read any of my work without a subscription to Seeking Alpha Premium!We do note, however, that ...

CMS Energy Corporation (CMS) is making systematic investments to enhance its operations. It is also benefiting from delivering high-quality services to its consumers. The company is expanding its renewable power portfolio while eliminating coal-generating units.However, this Zacks Rank #3 (Hold) company is exposed to unfavorable costs associated with the shutdown of solid waste disposal facilities for coal ash.Factors Acting in Favor of CMS CMS Energy is investing heavily in infrastructure renovations and r ...

Group 1: Company Initiatives - CMS Energy's subsidiary, Consumers Energy, has successfully eliminated 72,000 outages in 2024 through significant investments in smart technology, particularly Automatic Transfer Reclosers (ATRs), saving over 350,000 hours of potential power loss for customers this year [1][2] - Consumers Energy's Reliability Roadmap aims to ensure fewer than 100,000 customers lose power during major storms and to restore power within 24 hours after outages [2] - The company is inspecting over 1,100 substations using infrared cameras, which saved customers nearly 20 million minutes of downtime last year [5] Group 2: Infrastructure Investment - CMS Energy plans to invest $13.6 billion over the next five years to maintain and upgrade gas infrastructure and electric distribution systems, improve customer satisfaction, and facilitate clean energy transformation [6] - The aging electrical grid requires ongoing investment to upgrade and replace outdated equipment, ensuring a consistent and reliable power supply [3] Group 3: Industry Trends - Leading utility companies globally intend to invest over $116 billion annually in clean power generation and power system grid infrastructure in the coming years [4] - Other electric utilities, such as DTE Energy, Consolidated Edison, and American Electric Power, are also making significant capital investments to strengthen their infrastructure [7] Group 4: Peer Investment Strategies - DTE Energy plans to invest $25 billion over the next five years, reflecting an 8.7% increase from its previous investment plan, with a projected 4.7% year-over-year growth in 2025 sales [8] - Consolidated Edison has a capital expenditure plan of $28.05 billion for 2024-2028, having spent $4.51 billion in 2023, with a projected 4.2% year-over-year growth in 2024 sales [9] - American Electric Power plans to invest $43 billion from 2024 to 2028, with $7.4 billion expected in 2024 [10] Group 5: Stock Performance - CMS shares have gained 21.8% year-to-date, slightly outperforming the industry's growth of 21.6% [12]

The annual report, based on expert analysis and comprehensive data, recognized Wix as a leader in web accessibility and SEO   NEW YORK — Wix.com  (NASDAQ: WIX), the leading SaaS website builder platform globally1, earned top recognition in the 2024 Web Almanac report as the Most Accessible Website Platform CMS and Best SEO Performer. These distinctions reflect Wix's commitment to empowering users with tools that prioritize website accessibility and optimize discoverability.  This report, produced by the HTT ...

Core Insights - HeartSciences has received approval from the Centers for Medicare & Medicaid Services (CMS) for reimbursement of its AI-ECG technology under the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule, which is a significant milestone for the commercialization of its products [1][2] - The reimbursement payment rate for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm is expected to be $125, contingent upon FDA clearance [1] - The company aims to enhance the clinical utility of ECGs through innovative AI-based technology, targeting improvements in cardiac screening, particularly in frontline clinical settings [2] Company Overview - Heart Test Laboratories, Inc., operating as HeartSciences, focuses on applying AI technology to ECGs to improve their diagnostic capabilities and expand their clinical utility [2] - The company possesses one of the largest libraries of AI-ECG algorithms and is developing solutions that can be deployed on a cloud-based platform or its proprietary MyoVista® wavECG™ device [2] - The MyoVista® product is designed to provide both conventional ECG information and diagnostic insights related to cardiac dysfunction, traditionally available only through cardiac imaging [2]

Core Insights - Limaca Medical Ltd.'s Precision-GI™ motorized endoscopic biopsy device has received transitional pass-through (TPT) payment approval from the Centers for Medicare & Medicaid Services (CMS), enhancing patient access to this innovative technology starting January 1, 2025 [1][2] - The Precision-GI™ device aims to improve biopsy results for patients with suspected gastrointestinal cancers, including pancreatic and liver cancers, and has previously received FDA Breakthrough Device Designation and clearance [1][2] Company Overview - Limaca Medical is an Israel-based company focused on enhancing endoscopic biopsy results for patients with potentially life-threatening cancers, supported by various investors including the Israeli Innovation Authority and The Trendlines Group [5] - The company is also pursuing market entry in Japan in collaboration with HekaBio [4][5] Product Details - The Precision-GI™ device features a motorized, automated, rotating cutting mechanism that allows for superior tissue acquisition quality, reducing blood content and procedure time compared to traditional endoscopic biopsy devices [3] - The device has begun its U.S. market entry after performing its first cases in September 2024, addressing the significant global incidence of pancreatic cancer, which recorded 510,992 new cases in 2022 [4]